Survey: 3M Canadians on GLP-1 Drugs Like Ozempic, Reshaping Eating and Spending

In a striking revelation from a recent Leger Healthcare survey, approximately three million Canadian adults are currently taking GLP-1 drugs such as Ozempic or Mounjaro. This poll, conducted online with 1,536 Canadians aged 18 and over from February 6 to 9, 2026, highlights how these medications are profoundly influencing eating behaviors, food cravings, and consumer spending patterns across the country. Extrapolated from 2025 adult population statistics, the findings underscore GLP-1 drugs' rapid mainstream adoption in Canada.

What Are GLP-1 Drugs and How Do They Work?

GLP-1 receptor agonists, like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), mimic the glucagon-like peptide-1 hormone. This hormone regulates blood sugar by stimulating insulin release, slowing gastric emptying, and signaling fullness to the brain. The result? Significant reductions in appetite and food intake, which explains the survey's reports of decreased appetite in more than half of users and 40% experiencing fewer cravings.

Originally developed for type 2 diabetes management, these drugs have gained fame for weight loss due to their effects on metabolic health. In Canada, where obesity affects over 30% of adults, GLP-1 drugs address a critical need, but access remains uneven.

Key Survey Findings: Eating Habits Transformed

The Leger Healthcare poll paints a clear picture of behavioral shifts among GLP-1 users:

• More than half reported decreased appetite.
• 40% noted fewer food cravings.
• About 30% are dining out or ordering takeout less frequently.
• 35% are opting for smaller portions, lighter or healthier options, or leaving meals unfinished.
• A notable 36% have reduced alcohol consumption.
• One-third are purchasing more fresh fruits, vegetables, and protein-rich foods.

These changes align with the drugs' mechanisms: delayed stomach emptying reduces hunger signals, promoting sustainable dietary adjustments rather than restrictive dieting.

Insurance and Cost Breakdown Among Users

Among those taking GLP-1s:

• 25% pay fully out-of-pocket, where monthly costs can reach hundreds of dollars.
• 28% have full coverage via private or public insurance.
• Almost half have partial coverage.

Shifts in Spending Beyond the Grocery Aisle

GLP-1 use extends its influence to broader consumer habits. The survey indicates increased spending on clothes, personal care products, beauty services, and fitness-related items. "GLP-1s are no longer a niche health topic. They're a mainstream consumer and health-care story," said Melicent Lavers-Sailly, vice-president of research at Leger Healthcare. "What the research found is that the impact of GLP-1s is showing up in shopping baskets and behaviours, not just prescriptions."

This ripple effect could reshape retail sectors in Canada, from decreased fast-food sales to boosted demand for activewear and gym memberships.

Reasons for Taking GLP-1 Medications

Weight loss is the top motivator, cited by 58% of those taking or considering GLP-1 drugs. Diabetes follows at 42%. Additionally, 22% mentioned heart health, with men more likely than women to prioritize this benefit. Emerging evidence supports cardiovascular risk reduction with these drugs, making them appealing for metabolic syndrome patients.

Barriers for 2 Million Interested Canadians

The survey estimates two million Canadian adults want to start GLP-1 therapy but haven't. Key obstacles include:

• Lack of insurance coverage and high costs for about half.
• 36% deterred by side effect risks.
• More than half of interested individuals said insurance or lower-cost generics would sway their decision.

Common side effects are gastrointestinal, such as nausea, vomiting, constipation, and diarrhea. More severe issues like gallbladder inflammation or pancreatitis occur rarely, and most effects are minor, per physicians. Patients experiencing symptoms might benefit from tracking tools like Shotlee to monitor side effects and share data with doctors for better management.

Survey Methodology Notes

Leger Healthcare's online survey of 1,536 adults yielded extrapolations: 8% current users equating to 3 million, and 6% interested equating to over 2 million. While online polls lack traditional margins of error, a comparable probability sample would have ±2.5% (19/20 times). This report by The Canadian Press was first published March 3, 2026, with support from the Canadian Medical Association partnership.

What This Means for Canadian Patients

For those with obesity, diabetes, or heart health concerns, GLP-1 drugs offer proven benefits in appetite control and weight management. However, discuss eligibility with your healthcare provider—factors like BMI, comorbidities, and side effect tolerance matter. If cost is a barrier, explore public plans like those in Ontario or Quebec, or advocate for expanded coverage.

Compared to alternatives like older weight loss drugs (e.g., phentermine) or bariatric surgery, GLP-1s provide non-invasive, reversible options with metabolic bonuses. Long-term data shows sustained weight loss of 15-20% with lifestyle support.

Practical Guidance: Starting GLP-1 Therapy in Canada

1. Consult a doctor: Get screened for contraindications like thyroid cancer history.
2. Check coverage: Use provincial formularies or private insurers.
3. Start low, go slow: Titrate doses to minimize GI side effects.
4. Track progress: Monitor weight, A1C, and habits; apps like Shotlee can log medication schedules and symptoms.
5. Combine with lifestyle: The survey's buying shifts highlight pairing drugs with nutrition and exercise for best results.

Key Takeaways

• 3 million Canadians are on GLP-1s, driving appetite suppression and spending changes.
• Weight loss (58%) and diabetes (42%) lead motivations; heart health (22%) gains traction.
• Cost and side effects block 2 million potentials—insurance could unlock access.
• Behavioral shifts include less dining out, more healthy foods, and fitness investments.

Conclusion

This Leger survey signals GLP-1 drugs' transformation of Canadian health and consumer landscapes. Patients should weigh benefits against barriers with professionals, potentially reshaping metabolic health nationwide. Stay informed on coverage expansions and generics for broader access.